A groundbreaking phase 1 clinical trial has demonstrated that a novel vaccine combining protection against both Lassa fever and rabies is safe and effective in humans. The LASSARAB vaccine, which uses an inactivated rabies virus as a vector to deliver Lassa virus antigens, successfully triggered immune responses against both pathogens in healthy adult participants.
This milestone represents a significant advancement in global health efforts to combat Lassa fever, a deadly viral hemorrhagic fever endemic to West Africa. With approximately 300,000 people affected annually and 5,000 deaths reported each year, the development of an effective vaccine could substantially reduce disease burden in the region. The study, published in Nature Medicine, marks a critical step toward clinical protection against this neglected tropical disease. Read the full article on GMJ Newsroom.
Was this article helpful?
GMJ Brief · Announcement
📰 Read the full article: First Lassa Fever Vaccine Shows Promise in Early Human Trial →
